- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05423873
A Multi-Center, Open-label Study Evaluate the Efficacy and Tolerability of a Dual Skincare Regimen Treatment for Facial Hyperpigmentation and Photodamaged Skin in Patients Exposed to Extrinsic Factors of Aging
A Multi-Center Clinical Trial to Evaluate the Efficacy and Tolerability for Treatment of Facial Hyperpigmentation and Photodamaged Skin With a Dual Regimen Treatment Containing Vitamin C and a Tinted SPF 45 Moisturizer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This open-label, multi-center clinical trial was conducted to evaluate the dual skincare regimen of vitamin C serum and moisturizing sunscreen SPF 45 to improve facial hyperpigmentation and photodamage when used twice daily over the course of 12 weeks by healthy women with Fitzpatrick skin type I - V, moderate to severe global face hyperpigmentation and moderate global face photodamage.
Efficacy and tolerability will be assessed through clinical grading at baseline, weeks 4, 8 and 12. Efficacy evaluation for hyperpigmentation (mottled), hyperpigmentation (discrete), overall photodamage, clarity/brightness, overall appearance, skin tone evenness (redness), fine lines and wrinkles. Investigator and subject tolerability, self-assessment questionnaire and clinical VISIA photography will be completed at baseline, weeks 4, 8 and 12. Subject testimonials will be completed at week 12.
A total of 33 subjects completed study participation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Solana Beach, California, United States, 92075
- Art of Skin MD
-
-
Colorado
-
Greenwood Village, Colorado, United States, 80111
- About Skin
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Brian S. Biesman, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women between the ages of 35 and 60 years old.
- Women with Fitzpatrick skin type I-V.
- Subjects must have moderate to severe global face hyperpigmentation.
- Subjects must have moderate global face photodamage.
- Subjects must have no known medical conditions that, in the investigator's opinion, may interfere with study participation.
- Subjects must be willing to provide verbal understanding and written informed consent.
Exclusion Criteria:
- Subjects which had a health condition and/or pre-existent dormant dermatological disease on the face.
- Subjects that are unwilling to comply with the protocol.
- Female subjects who are pregnant, breast feeding, or planning a pregnancy.
- Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study products.
- Subjects who have a history of skin cancer.
- Subjects who have observable suntan, sunburn, scars, nevi, tattoo, excess hair, etc. or other dermatological condition on the face that might influence the test results in the opinion of the investigator.
- Subjects who have routinely used any anti-aging, anti-wrinkles, antioxidants treatments and skin-firming products less than 30 days prior to the study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Vitamin C Serum and Moisturizing Sunscreen SPF 45
Dual Regimen: Vitamin C Serum Tinted Moisturizing Sunscreen SPF 45 |
Gentle cleansing lotion to be used by study participants twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in clinical efficacy of hyperpigmentation versus Baseline
Time Frame: 12 weeks
|
The primary efficacy endpoint will be the Investigator Clinical Grading using Modified Griffith's 10-point Scale. A change in scores at week 4, week 8 and week 12 in comparison to baseline indicates an improvement for the indicated parameter. Global facial hyperpigmentation will be assessed on each subject's face using a modified Griffiths' 10-point scale according to the following numerical definitions (half-point scores may be used as necessary to more accurately describe the skin condition): 0 = none (best possible condition); 1 to 3 = mild; 4 to 6 = moderate;7 to 9 = severe (worst possible condition). The lower the score equates to the best possible outcome. |
12 weeks
|
Lack of Significant Increase in Objective Investigator Tolerability Parameters at week 4, 8, 12 compared to Baseline
Time Frame: 12 weeks
|
The primary tolerability endpoint will be favorable analysis of the Investigator Tolerability Assessment of Erythema, Edema and Dryness. A change in scores or lack of significant change at week 4, week 8 and week 12 in comparison to Baseline indicates tolerability/safety of the test material. Four point scale with a lower score indicating a better outcome. Example for Erythema: 0 = None No erythema of the treatment area, 1 = Mild Slight, but definite redness of the treatment area, 2 = Moderate Definite redness of the treatment area, 3 = Severe Marked redness of the treatment area |
12 weeks
|
Incidence and severity of adverse events
Time Frame: 12 weeks
|
The primary safety endpoint will be determined by the incidence and severity of adverse events in healthy subjects through-out the length of the study.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in clinical efficacy of photodamage versus Baseline
Time Frame: 12 weeks
|
The secondary efficacy endpoint will be the Investigator Clinical Grading using Modified Griffith's 10-point Scale. A change in scores at week 4, week 8 and week 12 in comparison to baseline indicates an improvement for the indicated parameter. Global facial photodamage will be assessed on each subject's face using a modified Griffiths' 10-point scale according to the following numerical definitions (half-point scores may be used as necessary to more accurately describe the skin condition): 0 = none (best possible condition); 1 to 3 = mild; 4 to 6 = moderate;7 to 9 = severe (worst possible condition). The lower the score equates to the best possible outcome. |
12 weeks
|
Lack of Significant Increase in Objective Subject Tolerability Parameters at week 4, 8, 12
Time Frame: 12 weeks
|
The primary tolerability endpoint will be favorable analysis of the Subject Tolerability Assessment of Erythema, Edema and Dryness. A change in scores or lack of significant change at week 4, week 8 and week 12 in comparison to Baseline indicates tolerability/safety of the test material. Four point scale with a lower score indicating a better outcome. Example for Erythema: Erythema 0=None No erythema of the treatment area,1=Mild Slight, but definite redness of the treatment area, 2=Moderate Definite redness of the treatment area, 3=Severe Marked redness of the treatment area |
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RS-2020-04
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperpigmentation
-
Academy of Laser Dentistry - Gulf Laser ChapterDamascus UniversityCompletedHyperpigmentation; Melanin | Laser-Induced HyperpigmentationQatar
-
Chang Gung Memorial HospitalScientis Pharma SARecruitingHyperpigmentation; PostinflammatoryTaiwan
-
Kasr El Aini HospitalCompletedPeriorbital HyperpigmentationEgypt
-
Damascus UniversityCompletedPeriorbital HyperpigmentationSyrian Arab Republic
-
Henry Ford Health SystemCompletedPost-inflammatory HyperpigmentationUnited States
-
Universal Skincare InstituteLavish BeautyCompletedPostinflammatory HyperpigmentationUnited States
-
Cairo UniversityCompletedMelanin Hyperpigmentation
-
Cairo UniversityUnknownPost Inflammatory Hyperpigmentation
-
Cryonove PharmaCEISO; DermatechCompletedPost-inflammatory HyperpigmentationSouth Africa
-
Cosmetique Active InternationalCompletedAcne | Postinflammatory HyperpigmentationUnited Arab Emirates
Clinical Trials on Gentle Cleansing Lotion, Revision Skincare
-
Revision SkincareCompletedWrinkle | Photoaging | Fine LinesUnited States
-
Revision SkincareStephens & Associates, Inc.CompletedWrinkle | Photoaging | Fine LinesUnited States
-
Revision SkincareKGL, Inc.CompletedWrinkle | PhotoagingUnited States
-
Revision SkincareCompletedPhotoaging | Anti-agingUnited States
-
Revision SkincareValidated Claim SupportCompletedWrinkle | Periorbital Edema | Fine Lines | Periorbital HyperpigmentationUnited States
-
Revision SkincareCompletedWrinkle | Skin Laxity | PhotoagingUnited States
-
De La Salle University Medical CenterPinnaclife Inc.TerminatedDiabetic Foot | Ulcer | Leg Ulcer | Skin UlcerPhilippines
-
Mayo ClinicCompletedSkin AgingUnited States